Mutations driving leukemia identified

An international team of scientists has identified novel genes associated with chronic lymphocytic leukemia through the analysis of high-throughput sequencing data.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Publication date: Available online 16 August 2019Source: Molecular and Cellular ProbesAuthor(s): Yan Li, Min Mao, Hong Liu, Xiaomin Wang, Zhen Kou, Yuling Nie, Yichun Wang, Zengsheng Wang, Qin Huang, Tao Lang, Zailinuer Gu, Li An, Xiaoyan Zhang, Lin FuAbstractThe abnormal expression of miRNAs may play critical roles in the occurrence, development and prognosis of chronic lymphocytic leukemia (CLL), with potential ethnic differences being involved. p53 and immunoglobulin heavy chain variable region gene (IGVH) mutations were monitored and miRNA profile screening of CD19 + cells from Uygur CLL patients was performed, ana...
Source: Molecular and Cellular Probes - Category: Molecular Biology Source Type: research
Condition:   Chronic Lymphocytic Leukemia Intervention:   Drug: Obinutuzumab Sponsors:   Deok-Hwan Yang;   Roche Pharma AG Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
While aberrant protein glycosylation is a recognised characteristic of human cancers, advances in glycoanalytics continue to discover new associations between glycoproteins and tumourigenesis. This glycomics ‐centric study investigates a possible link between protein paucimannosylation, an under‐studied class of humanN‐glycosylation [Man1 ‐3GlcNAc2Fuc0 ‐1], and human cancers. The paucimannosidic glycans (PMGs) of 34 cancer cell lines and 133 tissue samples spanning 11 cancer types and matching non ‐cancerous specimens were profiled from 467 published and unpublished PGC‐LC‐MS/MSN‐glycome datasets collecte...
Source: Proteomics - Category: Biochemistry Authors: Tags: Research Article Source Type: research
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Clinical Communication to the Editor Source Type: research
We report a study aimed to provide a "snapshot" of the prevalence of mutations in a real-life CLL cohort still on ibrutinib after at least 3 years of treatment. Of 204 patients who initiated ibrutinib via an early-access program at 29 French Innovative Leukemia Organization (FILO) centers, 63 (31%) were still on ibrutinib after 3 years and 57 provided a fresh blood sample. Thirty patients had a CLL clone ≥0.5 x 109/L, enabling next-generation sequencing (NGS); BTK and PLCG2 mutations were detected in 57% and 13% of the NGS samples, respectively. After median follow-up of 8.5 months from sample collection, the ...
Source: Blood - Category: Hematology Authors: Tags: Lymphoid Neoplasia, Brief Reports Source Type: research
This study examined the expression pattern of FCRL1 in B-cell non-Hodgkin's lymphoma patients using real-time PCR and flow cytometry. The results revealed higher levels of FCRL1 expression in diffuse large B-cell lymphoma, hairy cell leukemia, and Burkitt lymphoma patients compared with control groups. There was a significant reduction in the levels of FCRL1 expression in chronic lymphocytic leukemia and mantle cell lymphoma patients compared with healthy individuals. These findings suggest FCRL1 as an excellent marker for the prognosis or immunotherapy of B-cell malignancies.
Source: Leukemia Research Reports - Category: Hematology Source Type: research
Abstract PMID: 31413095 [PubMed - as supplied by publisher]
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
eurer M Abstract Ibrutinib is the first clinically approved inhibitor of Bruton's tyrosine kinase, an enzyme that is essential for survival and proliferation of B‑cells by activating the B‑cell receptor signalling pathway. Ibrutinib has been shown to be highly effective in B‑cell malignancies in clinical trials and is recommended in current international guidelines as a first and/or second line treatment of chronic lymphocytic leukemia. The drug has a favorable tolerability and safety profile but the occurrence of specific side effects (e.g. atrial fibrillation, bleeding and hypertension) may compl...
Source: Wiener Klinische Wochenschrift - Category: General Medicine Authors: Tags: Wien Klin Wochenschr Source Type: research
This study is aimed to investigate the prognostic effect of clinic, laboratory and flow cytometric analysis in CLL patients. Newly diagnosed 55 CLL cases were divided into two groups, as stable disease (Group 1) and progressive disease (Group 2). Group 1 included those who did not require any treatment since diagnosis and those who did not progress after receiving the first step anti CLL treatment. Group 2 included the patients who received  ≥ 2 steps treatment. The relation between the two groups was analyzed statistically in terms of clinical, laboratory and flow cytometric findings. Twenty patients (36....
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Genetics | Leukemia | Science